Erin McCaskill Newman

Erin McCaskill Newman is currently serving as the Chief Development Officer at Iolyx Therapeutics, a Series A biotech company with a clinical stage therapeutic. Prior to this role, Erin worked as a Principal Biotech Consultant at Erin Newman Consulting, offering strategic support in portfolio management and global operations. With a background in clinical operations and program management, Erin has held various positions at Alkahest, Inc. and Cotherix Inc./Actelion Pharmaceuticals Inc. Erin earned a BS in Microbiology and Biochemistry from UC Santa Barbara.